|
Latest
news
10 December
2003
Use of
Selective Serotonin Reuptake Inhibitors (SSRIs) in children and
adolescents with major depressive disorder (MDD) - only fluoxetine
(Prozac) shown to have a favourable balance of risks and benefits for the
treatment of MDD in the under 18s
On the basis of a review of the
safety and efficacy of the SSRI class in the treatment of paediatric major
depressive disorder undertaken by the Expert Working Group of the
Committee on Safety of Medicines (CSM), the CSM has advised that the
balance of risks and benefits for the treatment of major depressive
disorder (MDD) in under 18s is judged to be unfavourable for sertraline,
citalopram and escitalopram and unassessable for fluvoxamine. Only
fluoxetine (Prozac) has been shown in clinical trials to have a favourable
balance of risks and benefits for the treatment of MDD in the under 18s.
The following documents are available:
3 December
2003
Use of
hormone replacement therapy in the prevention of osteoporosis: important
new information
Hormone replacement therapy (HRT) is no longer
recommended as first choice of therapy for prevention of osteoporosis.This
follows a European-wide review of the balance of risks and benefits of HRT
in response to growing concerns about the safety of HRT in long-term use.
The following documents are available:
1 December
2003
Change in dose of emergency contraceptive
(Levonelle)
In response to new data from a World Health
Organisation (WHO) study, the Committee on Safety of Medicines has advised
that the dose should change from two tablets taken 12 hours apart to a
single dose of two tablets taken together. The MHRA press statement
is attached here.
©
Crown copyright 2003
| 
